Precision BioSciences, Inc.
DTILHealthcare|Biotechnology|US
$10.60
+0.73 (+7.40%)
Tangible Book / Share
$1.85
Cash / Share
$2.98
Financials
Financial Snapshot
Market Cap
$292.6M
Enterprise Value
$238.6M
Revenue (TTM)
$45.0M
Net Income (TTM)
-$38.5M
Cash & Investments
$81.8M
Net Cash
$54.1M
Free Cash Flow (TTM)
-$51.8M
Operating CF (TTM)
-$51.8M
Debt/Equity
0.54
Cash Runway & Burn Rate
Cash on Hand
$81.8M
Quarterly Burn
$12.9M
Monthly Burn
$4.3M
Est. Runway
~6.3 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $93.4M | $62.8M | $103.2M | $180.9M | $89.8M | $143.7M | $189.6M | $116.7M | $86.3M | $115.6M | $81.8M | |
| Operating Cash Flow | $92.3M | -$24.2M | -$51.7M | -$73.6M | -$87.4M | -$10.9M | -$45.8M | -$84.1M | -$58.4M | -$65.8M | -$51.8M | |
| Free Cash Flow | $90.2M | -$29.7M | -$67.4M | -$98.3M | -$92.4M | -$16.7M | -$49.1M | -$86.4M | -$58.7M | -$65.9M | -$51.8M | |
| Capital Expenditure | -$2.1M | -$5.6M | -$15.7M | -$24.7M | -$5.0M | -$5.8M | -$3.3M | -$2.3M | -$250.0K | -$85.0K | -$52.0K | |
| Financing Cash Flow | -$12.4M | -$937.0K | $107.8M | $176.0M | $1.3M | $70.5M | $95.0M | $5.4M | $50.5M | $95.2M | $89.2M |
R&D Spending
R&D (TTM)
$52.7M
R&D Intensity
117.0%
R&D Growth vs Prior
-2.7%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.0M | $6.5M | $10.9M | $22.2M | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M | $45.0M | |
| R&D Expense | $9.1M | $20.3M | $45.1M | $82.4M | $98.1M | $115.2M | $46.1M | $53.4M | $59.6M | $54.2M | $52.7M | |
| R&D % of Revenue | 129.8% | 313.4% | 414.6% | 370.6% | 403.8% | 99.7% | 183.8% | 109.5% | 86.7% | 158.1% | 117.0% | |
| SG&A | $6.1M | $8.0M | $13.7M | $27.0M | $36.1M | $39.7M | $41.3M | $39.1M | $35.3M | $32.2M | $28.5M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.0M | $6.5M | $10.9M | $22.2M | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M | $45.0M | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $580.0K | |
| Gross Profit | $7.0M | $6.5M | $10.9M | $22.2M | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M | $44.5M | |
| R&D | $9.1M | $20.3M | $45.1M | $82.4M | $98.1M | $115.2M | $46.1M | $53.4M | $59.6M | $54.2M | $52.7M | |
| SG&A | $6.1M | $8.0M | $13.7M | $27.0M | $36.1M | $39.7M | $41.3M | $39.1M | $35.3M | $32.2M | $28.5M | |
| Operating Income | -$8.8M | -$22.0M | -$47.9M | -$87.2M | -$109.8M | -$39.4M | -$62.3M | -$43.7M | -$26.2M | -$52.1M | -$36.2M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $182.0K | $0.00 | $132.0K | $1.1M | $2.2M | $1.8M | $1.4M | $1.3M | |
| Pretax Income | -$8.3M | -$21.1M | -$46.0M | -$92.9M | -$109.0M | -$30.6M | -$72.9M | -$42.5M | $7.2M | -$46.6M | -$39.4M | |
| Net Income | -$8.3M | -$21.1M | -$46.0M | -$92.9M | -$109.0M | -$30.6M | -$111.6M | -$61.3M | $7.2M | -$45.7M | -$38.5M | |
| EPS (Diluted) | -0.49 | -18.81 | -28.17 | -59.50 | -62.85 | -15.60 | -38.10 | -15.96 | 1.04 | -3.56 | -1.24 | |
| EBITDA | -$8.2M | -$20.4M | -$43.7M | -$87.4M | -$99.2M | -$20.3M | -$62.8M | -$32.0M | $13.5M | -$42.4M | -$48.8M | |
| Shares Out. (M) | 16.74 | 1.12 | 1.63 | 1.40 | 1.73 | 1.96 | 2.93 | 3.84 | 6.88 | 12.83 | 27.43 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $93.4M | $62.8M | $103.2M | $180.9M | $89.8M | $143.7M | $189.6M | $116.7M | $85.9M | $110.8M | $81.7M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $413.0K | $4.8M | $148.0K | |
| Total Current Assets | $94.4M | $64.3M | $115.7M | $193.7M | $105.6M | $161.8M | $199.1M | $136.4M | $95.0M | $118.7M | $86.6M | |
| Total Assets | $98.4M | $72.7M | $138.6M | $235.2M | $150.2M | $211.5M | $238.2M | $159.8M | $136.4M | $154.4M | $120.4M | |
| Total Current Liabilities | $8.3M | $9.2M | $14.1M | $26.9M | $42.8M | $36.0M | $59.7M | $50.0M | $15.0M | $8.9M | $8.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.5M | $22.2M | $0.00 | $22.3M | $22.4M | $22.4M | |
| Total Liabilities | $103.2M | $99.1M | $98.6M | $96.9M | $105.7M | $120.3M | $177.7M | $140.9M | $80.0M | $62.2M | $68.6M | |
| Stockholders' Equity | -$4.7M | -$26.4M | $40.0M | $138.3M | $44.4M | $91.2M | $60.4M | $18.9M | $56.4M | $92.2M | $51.8M | |
| Retained Earnings | -$18.0M | -$39.1M | -$85.2M | -$177.1M | -$286.1M | -$316.7M | -$428.3M | -$489.6M | -$482.5M | -$528.2M | -$586.9M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $92.3M | -$24.2M | -$51.7M | -$73.6M | -$87.4M | -$10.9M | -$45.8M | -$84.1M | -$58.4M | -$65.8M | -$51.8M | |
| Capital Expenditure | -$2.1M | -$5.6M | -$15.7M | -$24.7M | -$5.0M | -$5.8M | -$3.3M | -$2.3M | -$250.0K | -$85.0K | -$52.0K | |
| Free Cash Flow | $90.2M | -$29.7M | -$67.4M | -$98.3M | -$92.4M | -$16.7M | -$49.1M | -$86.4M | -$58.7M | -$65.9M | -$51.8M | |
| Investing Cash Flow | -$2.1M | -$5.5M | -$15.7M | -$24.7M | -$5.0M | -$5.8M | -$3.3M | $5.8M | -$215.0K | -$634.0K | -$638.0K | |
| Financing Cash Flow | -$12.4M | -$937.0K | $107.8M | $176.0M | $1.3M | $70.5M | $95.0M | $5.4M | $50.5M | $95.2M | $89.2M | |
| Issuance of Stock | $49.0K | $0.00 | $171.0K | $136.4M | $0.00 | $60.5M | $74.3M | $5.0M | $50.2M | $95.2M | $89.2M | |
| Repurchase of Stock | $0.00 | -$952.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $39.5M | $0.00 | $2.5M | $19.8M | $0.00 | -$37.0K | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $419.0K | $2.5M | $0.00 | $13.8M | $16.5M | $19.2M | $14.0M | $12.6M | $10.2M | $8.4M | |
| Net Change in Cash | $77.8M | -$30.6M | $40.4M | $77.7M | -$91.1M | $53.9M | $45.9M | -$72.9M | -$8.2M | $28.7M | $36.8M |
Dilution Tracker
Shares outstanding grew 639.5% over 5 years — significant dilution
Shares Outstanding
28M
5-Year Share Growth
+639.5%
Stock Issuance (TTM)
$89.2M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 16.74 | 1.12 | 1.63 | 1.40 | 1.73 | 1.96 | 2.93 | 3.84 | 6.88 | 12.83 | 27.43 | |
| Change vs Prior % | — | -93.3% | 45.7% | -14.3% | 23.9% | 12.8% | 49.8% | 31.1% | 79.2% | 86.3% | 113.9% | |
| Stock Issuance | $49.0K | $0.00 | $171.0K | $136.4M | $0.00 | $60.5M | $74.3M | $5.0M | $50.2M | $95.2M | $89.2M | |
| Stock Repurchase | $0.00 | -$952.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $419.0K | $2.5M | $0.00 | $13.8M | $16.5M | $19.2M | $14.0M | $12.6M | $10.2M | $8.4M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 98.7% | |
| Operating Margin % | -125.8% | -338.9% | -440.2% | -392.1% | -452.2% | -34.1% | -248.3% | -89.8% | -38.1% | -152.2% | -80.3% | |
| Net Margin % | -117.6% | -325.4% | -423.0% | -417.6% | -448.9% | -26.5% | -444.8% | -125.8% | 10.4% | -133.4% | -85.6% | |
| EBITDA Margin % | -116.7% | -314.9% | -401.4% | -392.9% | -408.5% | -17.5% | -250.2% | -65.8% | 19.7% | -123.8% | -108.4% | |
| FCF Margin % | 1285.8% | -458.6% | -619.3% | -442.0% | -380.6% | -14.4% | -195.5% | -177.3% | -85.4% | -192.4% | -115.0% | |
| ROE % | 173.7% | 80.0% | -115.2% | -67.1% | -245.4% | -33.6% | -184.7% | -325.1% | 12.7% | -49.6% | -58.1% | |
| ROA % | -8.4% | -29.0% | -33.2% | -39.5% | -72.6% | -14.5% | -46.9% | -38.4% | 5.3% | -29.6% | -32.0% | |
| ROIC % | -9.8% | -34.6% | -38.5% | -41.9% | -100.5% | -22.2% | -34.6% | -32.8% | -21.3% | -35.5% | -31.8% | |
| R&D / Revenue % | 129.8% | 313.4% | 414.6% | 370.6% | 403.8% | 99.7% | 183.8% | 109.5% | 86.7% | 158.1% | 117.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | -7.6% | 67.8% | 104.3% | 9.2% | 375.7% | -78.3% | 94.1% | 41.0% | -50.1% | |
| Gross Profit | 0.0% | -7.6% | 67.8% | 104.3% | 9.2% | 375.7% | -78.3% | 94.1% | 41.0% | -50.1% | |
| Operating Income | 0.0% | -148.9% | -118.0% | -82.0% | -25.9% | 64.1% | -58.2% | 29.8% | 40.2% | -99.3% | |
| Net Income | 0.0% | -155.8% | -118.2% | -101.7% | -17.4% | 71.9% | -264.8% | 45.1% | 111.7% | -738.0% | |
| EPS (Diluted) | 0.0% | -3738.8% | -49.8% | -111.2% | -5.6% | 75.2% | -144.2% | 58.1% | 106.5% | -442.3% | |
| Operating Cash Flow | 0.0% | -126.2% | -114.0% | -42.4% | -18.7% | 87.6% | -321.6% | -83.8% | 30.5% | -12.7% | |
| Free Cash Flow | 0.0% | -133.0% | -126.7% | -45.8% | 6.0% | 82.0% | -194.6% | -76.1% | 32.1% | -12.3% | |
| R&D Expense | 0.0% | 123.3% | 122.0% | 82.7% | 19.0% | 17.5% | -60.0% | 15.7% | 11.6% | -9.0% | |
| SG&A Expense | 0.0% | 31.4% | 70.6% | 97.7% | 33.4% | 10.0% | 4.1% | -5.3% | -9.7% | -8.7% | |
| Total Assets | 0.0% | -26.1% | 90.7% | 69.7% | -36.2% | 40.9% | 12.6% | -32.9% | -14.6% | 13.2% | |
| Book Value / Share | 0.0% | -8184.8% | 204.0% | 304.1% | -74.1% | 81.9% | -55.7% | -76.2% | 68.1% | -12.9% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -13.4% | 173.9% | 25.3% | -3.9% | -4.1% | |
| Diluted Shares | 0.0% | -93.3% | 45.7% | -14.3% | 23.9% | 12.8% | 49.8% | 31.1% | 79.2% | 86.3% |
Valuation
P/E (TTM)At Loss
P/S6.50
10Y Low / Med / High0.38 / 17.87 / 1248.37
P/B5.62
10Y Low / Med / High0.46 / 4.22 / 21.40
EV/EBITDAAt Loss
10Y Low / Med / High0.68 / 0.96 / 1.35
EV/Revenue5.30
10Y Low / Med / High2.59 / 69.09 / 1235.05
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$1.85
Net Current Assets / Share
$0.65
Graham Net-Net
$0.48
Cash / Share
$2.98
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1067.76 | -27.81 | -18.57 | -7.00 | -3.98 | -14.23 | -0.94 | -0.69 | 3.63 | -1.17 | -8.62 | |
| P/S Ratio | 1248.37 | 90.52 | 78.57 | 26.23 | 17.87 | 3.76 | 4.17 | 0.86 | 0.38 | 1.56 | 6.50 | |
| P/B Ratio | -1844.03 | -22.26 | 21.40 | 4.22 | 9.77 | 4.76 | 1.73 | 2.23 | 0.46 | 0.58 | 5.62 | |
| EV/EBITDA | -1058.12 | -25.67 | -17.21 | -4.61 | -3.58 | -14.79 | 0.96 | 1.35 | -2.20 | 0.68 | -4.89 | |
| EV/Revenue | 1235.05 | 80.83 | 69.09 | 18.10 | 14.60 | 2.59 | -2.39 | -0.89 | -0.43 | -0.84 | 5.30 |
Analyst Estimates & Quality
Altman Z-Score
-4.52
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $12.7M | $8.2M | $19.8M |
| Net Income | -$44.2M | -$35.0M | -$23.5M |
| EPS | $-3.45 | $-2.73 | $-1.89 |
| # Analysts (EPS) | 3 | 3 | 4 |
Revenue Segments
By Product
| Segment | 2019 | 2020 | 2021 | 2025 |
|---|---|---|---|---|
| Food Segment | $1.6M | $2.4M | $3.8M | — |
| Therapeutics Segment | $20.6M | $21.9M | $111.7M | — |
| License | — | — | — | $8.0M |